Publications - March 2022
Preprint and peer-reviewed publications from RECOVER’s studies
The impacts of healthcare professionals (HCPs) being research participants are often neglected. As professionals, they tend to be perceived as ‘immune’ to many negative effects of sharing their experiences. However, in the context of an ongoing global pandemic such as COVID-19, these assumptions can be clearly challenged. This article draws on researchers’ experiences of conducting single and longitudinal qualitative interviews with HCPs during the COVID-19 pandemic in Europe during 2020.
The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. The ongoing adaptive platform trial REMAP-CAP therefore investigated this. 1557 critically ill adult patients with COVID-19 were enrolled between October 30, 2020, and June 23, 2021, from 105 sites in 8 countries and followed up for 90 days. Patients were randomized to receive either open-label aspirin, a P2Y12 inhibitor, or no antiplatelet therapy. Interventions were continued in the hospital for a maximum of 14 days and were in addition to anticoagulation thromboprophylaxis. Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support-free days within 21 days.